We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Med1Online announced that it has entered into an agreement with Toshiba America
Medical Systems to be an exclusive Internet distributor for the company's Nemio
ultrasound product line in the U.S.
Genetronics Biomedical, a late-stage developer of
oncology and other therapies using electroporation to deliver drugs and nucleic
acids, announced that its subsidiary, Genetronics, has been granted another
patent for a vascular application of its technology, namely U.S. Patent Number
6,865,416, entitled "Electrically Induced Vessel Vasodilation."
Ikonisys has announced the execution of two agreements that grant it license
and supply rights to certain DNA probe technology for use with its Celloptics
technology platform.
Enpath Medical has received CE approval from the EU to begin marketing its steroid
epicardial lead in Europe for one of its two contract customers for this product.
Advanced Neuromodulation Systems (ANS) has received an FDA investigational device
exemption (IDE) approval to implant 160 patients at 12 sites to investigate
the safety and efficacy of the ANS Libra Deep Brain Stimulation (DBS) System
to treat essential tremor.
Thoratec has filed for approval to CE Mark its HeartMate II LVAS (left ventricular
assist system), the approval of which would allow the commercial launch of the
device in Europe.
Southwestern Medical Solutions announced that it has contracted the firm Instant
Diagnostics to conduct final scientific support data studies on its Labguard
product line.
ThromboScience, a provider of blood tests that determine cardiovascular risk,
announced that it has measured a new risk factor that strongly predicts complications
from heart disease in patients who have had coronary artery stenting.
HealthSouth completed a $715 million refinancing arrangement that the company's
chief executive called "another significant step" toward rectifying
18 months of fraud-related issues.